RESUMO
PURPOSE: To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria. METHODS: Spectral-domain optical coherence tomography and fundus autofluorescence were used to investigate posterior segment changes. RESULTS: A 76-year-old man with paroxysmal nocturnal hemoglobinuria and hereditary spherocytosis was started on deferoxamine for iron overload secondary to previous blood transfusions. Four days after initiation of treatment, he developed bilateral reduced vision and metamorphopsia. He was noted to have bilateral central serous retinopathy. Symptoms and serous retinal detachment resolved rapidly following discontinuation of treatment. CONCLUSIONS: This case represents the first report of acute bilateral central serous retinopathy associated with deferoxamine therapy. Cessation of deferoxamine resulted in rapid visual recovery.
Assuntos
Coriorretinopatia Serosa Central/induzido quimicamente , Desferroxamina/efeitos adversos , Hemoglobinúria Paroxística/tratamento farmacológico , Sideróforos/efeitos adversos , Coriorretinopatia Serosa Central/diagnóstico por imagem , Coriorretinopatia Serosa Central/fisiopatologia , Angiofluoresceinografia , Fundo de Olho , Humanos , Sobrecarga de Ferro/tratamento farmacológico , Masculino , Tomografia de Coerência Óptica/métodos , Transtornos da Visão/induzido quimicamente , Transtornos da Visão/fisiopatologia , Baixa Visão/induzido quimicamente , Baixa Visão/fisiopatologia , Acuidade Visual/efeitos dos fármacosRESUMO
PURPOSE: Dexamethasone intravitreal implant is an approved preparation in the treatment of macular edema. The most common adverse reactions are increased intraocular pressure and cataract but the inadvertent injection of the dexamethasone implant into the capsular bag is an extremely rare event. METHODS: We present a case of a 78-year-old man treated for persistence of cystoid macular edema (CME) with Ozurdex intravitreal implant in which the procedure was complicated by the injection of the dexamethasone implant into the lens body and discuss the management. RESULTS: The patient underwent phacoemulsification of the lens, replacement of the Ozurdex, and implant of a 3-piece lens in the posterior chamber. CONCLUSIONS: The injection of an intravitreal dexamethasone implant (Ozurdex) into the lens body is an extremely rare complication that can be effectively and successfully managed with the surgical extraction of the implant from the lens body and implant of a 3-piece intraocular lens in the sulcus.
